AVEO Pharmaceuticals, Inc.

DB:VPA1 Stock Report

Market Cap: €480.3m

This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

AVEO Pharmaceuticals Past Earnings Performance

Past criteria checks 0/6

Key information

-2.9%

Earnings growth rate

32.7%

EPS growth rate

Biotechs Industry Growth-14.6%
Revenue growth rate51.0%
Return on equity-100.7%
Net Margin-30.8%
Last Earnings Update30 Sep 2022

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How AVEO Pharmaceuticals makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

DB:VPA1 Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 2294-296813
30 Jun 2279-366510
31 Mar 2261-41635
31 Dec 2142-53610
30 Sep 2126-585420
30 Jun 2114-564513
31 Mar 217-49345
31 Dec 206-36220
30 Sep 206-29160
30 Jun 2028-4130
31 Mar 20280120
31 Dec 19299110
30 Sep 193036110
30 Jun 196-3110
31 Mar 1964110
31 Dec 185-5110
30 Sep 184-24110
30 Jun 186-28100
31 Mar 186-6590
31 Dec 178-6590
30 Sep 178-7490
30 Jun 174-5390
31 Mar 174-2880
31 Dec 163-2780
30 Sep 166-28100
30 Jun 1620-15100
31 Mar 1620-12110

Quality Earnings: VPA1 is currently unprofitable.

Growing Profit Margin: VPA1 is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: VPA1 is unprofitable, and losses have increased over the past 5 years at a rate of 2.9% per year.

Accelerating Growth: Unable to compare VPA1's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: VPA1 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-15.1%).


Return on Equity

High ROE: VPA1 has a negative Return on Equity (-100.67%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2023/01/21 07:40
End of Day Share Price 2023/01/19 00:00
Earnings2022/09/30
Annual Earnings2021/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

AVEO Pharmaceuticals, Inc. is covered by 18 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Madhu KumarBaird
James BirchenoughBMO Capital Markets Equity Research
James BirchenoughBMO Capital Markets U.S. (Historical)